vs

Side-by-side financial comparison of PicoCELA Inc. (PCLA) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.

PicoCELA Inc. is the larger business by last-quarter revenue ($252.6M vs $164.7M, roughly 1.5× PTC THERAPEUTICS, INC.). PTC THERAPEUTICS, INC. runs the higher net margin — -82.0% vs -125.2%, a 43.2% gap on every dollar of revenue. PTC THERAPEUTICS, INC. produced more free cash flow last quarter ($-36.6M vs $-256.6M).

PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

PCLA vs PTCT — Head-to-Head

Bigger by revenue
PCLA
PCLA
1.5× larger
PCLA
$252.6M
$164.7M
PTCT
Higher net margin
PTCT
PTCT
43.2% more per $
PTCT
-82.0%
-125.2%
PCLA
More free cash flow
PTCT
PTCT
$219.9M more FCF
PTCT
$-36.6M
$-256.6M
PCLA

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
PCLA
PCLA
PTCT
PTCT
Revenue
$252.6M
$164.7M
Net Profit
$-316.2M
$-135.0M
Gross Margin
Operating Margin
-114.8%
-43.3%
Net Margin
-125.2%
-82.0%
Revenue YoY
-22.7%
Net Profit YoY
-104.8%
EPS (diluted)
$-1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCLA
PCLA
PTCT
PTCT
Q4 25
$164.7M
Q3 25
$211.0M
Q2 25
$178.9M
Q1 25
$252.6M
$1.2B
Q4 24
$213.2M
Q3 24
$196.8M
Q2 24
$186.7M
Q1 24
$210.1M
Net Profit
PCLA
PCLA
PTCT
PTCT
Q4 25
$-135.0M
Q3 25
$15.9M
Q2 25
$-64.8M
Q1 25
$-316.2M
$866.6M
Q4 24
$-65.9M
Q3 24
$-106.7M
Q2 24
$-99.2M
Q1 24
$-91.6M
Operating Margin
PCLA
PCLA
PTCT
PTCT
Q4 25
-43.3%
Q3 25
1.4%
Q2 25
-19.5%
Q1 25
-114.8%
82.5%
Q4 24
-76.2%
Q3 24
-27.7%
Q2 24
-21.5%
Q1 24
-21.6%
Net Margin
PCLA
PCLA
PTCT
PTCT
Q4 25
-82.0%
Q3 25
7.5%
Q2 25
-36.3%
Q1 25
-125.2%
73.7%
Q4 24
-30.9%
Q3 24
-54.2%
Q2 24
-53.1%
Q1 24
-43.6%
EPS (diluted)
PCLA
PCLA
PTCT
PTCT
Q4 25
$-1.63
Q3 25
$0.20
Q2 25
$-0.83
Q1 25
$10.04
Q4 24
$-0.85
Q3 24
$-1.39
Q2 24
$-1.29
Q1 24
$-1.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCLA
PCLA
PTCT
PTCT
Cash + ST InvestmentsLiquidity on hand
$456.8M
$1.9B
Total DebtLower is stronger
Stockholders' EquityBook value
$354.8M
$-205.3M
Total Assets
$1.2B
$2.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCLA
PCLA
PTCT
PTCT
Q4 25
$1.9B
Q3 25
$1.7B
Q2 25
$2.0B
Q1 25
$456.8M
$2.0B
Q4 24
$1.1B
Q3 24
$1.0B
Q2 24
$1.1B
Q1 24
$884.8M
Stockholders' Equity
PCLA
PCLA
PTCT
PTCT
Q4 25
$-205.3M
Q3 25
$-155.8M
Q2 25
$-206.5M
Q1 25
$354.8M
$-185.8M
Q4 24
$-1.1B
Q3 24
$-1.1B
Q2 24
$-980.2M
Q1 24
$-893.9M
Total Assets
PCLA
PCLA
PTCT
PTCT
Q4 25
$2.9B
Q3 25
$2.6B
Q2 25
$2.6B
Q1 25
$1.2B
$2.7B
Q4 24
$1.7B
Q3 24
$1.8B
Q2 24
$1.9B
Q1 24
$1.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCLA
PCLA
PTCT
PTCT
Operating Cash FlowLast quarter
$-245.6M
$-34.3M
Free Cash FlowOCF − Capex
$-256.6M
$-36.6M
FCF MarginFCF / Revenue
-101.6%
-22.3%
Capex IntensityCapex / Revenue
4.3%
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$702.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCLA
PCLA
PTCT
PTCT
Q4 25
$-34.3M
Q3 25
$-66.3M
Q2 25
$-58.3M
Q1 25
$-245.6M
$870.1M
Q4 24
$-30.0M
Q3 24
$-77.0M
Q2 24
$-71.5M
Q1 24
$70.8M
Free Cash Flow
PCLA
PCLA
PTCT
PTCT
Q4 25
$-36.6M
Q3 25
$-69.7M
Q2 25
$-59.6M
Q1 25
$-256.6M
$868.4M
Q4 24
$-33.8M
Q3 24
$-77.5M
Q2 24
$-78.8M
Q1 24
$61.2M
FCF Margin
PCLA
PCLA
PTCT
PTCT
Q4 25
-22.3%
Q3 25
-33.1%
Q2 25
-33.3%
Q1 25
-101.6%
73.8%
Q4 24
-15.8%
Q3 24
-39.4%
Q2 24
-42.2%
Q1 24
29.1%
Capex Intensity
PCLA
PCLA
PTCT
PTCT
Q4 25
1.4%
Q3 25
1.6%
Q2 25
0.7%
Q1 25
4.3%
0.1%
Q4 24
1.8%
Q3 24
0.3%
Q2 24
4.0%
Q1 24
4.6%
Cash Conversion
PCLA
PCLA
PTCT
PTCT
Q4 25
Q3 25
-4.17×
Q2 25
Q1 25
1.00×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PCLA
PCLA

Revenue from product$179.1M71%
Revenue from SaaS, Maintenance and others$42.4M17%
Revenue from product – related party$31.0M12%

PTCT
PTCT

Segment breakdown not available.

Related Comparisons